324 related articles for article (PubMed ID: 30169990)
1. Selecting immuno-oncology-based drug combinations - what should we be considering?
Festino L; Vanella V; Trojaniello C; Ascierto PA
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):971-985. PubMed ID: 30169990
[TBL] [Abstract][Full Text] [Related]
2. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.
Schmidt EV
Semin Immunopathol; 2019 Jan; 41(1):21-30. PubMed ID: 30374524
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
Kyi C; Postow MA
Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
[TBL] [Abstract][Full Text] [Related]
4. Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect - a glimpse to the future.
Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2018 Jul; 27(7):569-572. PubMed ID: 29958097
[TBL] [Abstract][Full Text] [Related]
5. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.
Lv JW; Li JY; Luo LN; Wang ZX; Chen YP
J Immunother Cancer; 2019 Jun; 7(1):159. PubMed ID: 31238988
[TBL] [Abstract][Full Text] [Related]
6. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
7. Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer.
Ingles Garces AH; Au L; Mason R; Thomas J; Larkin J
Expert Opin Investig Drugs; 2019 Aug; 28(8):695-708. PubMed ID: 31359805
[No Abstract] [Full Text] [Related]
8. CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy.
Szostak B; Machaj F; Rosik J; Pawlik A
Expert Opin Investig Drugs; 2019 Feb; 28(2):149-159. PubMed ID: 30577709
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
10. Novel approaches in cancer immunotherapy -- a light at the end of the tunnel.
Joshi M; Pal SK; Drabick JJ
Discov Med; 2016 Jun; 21(118):479-87. PubMed ID: 27448784
[TBL] [Abstract][Full Text] [Related]
11. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
Colombo MP
Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
Meng X; Liu Y; Zhang J; Teng F; Xing L; Yu J
Cancer Lett; 2017 Oct; 405():29-37. PubMed ID: 28688973
[TBL] [Abstract][Full Text] [Related]
13. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
Collins JM; Redman JM; Gulley JL
Expert Rev Vaccines; 2018 Aug; 17(8):697-705. PubMed ID: 30058393
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
Zhu X; Lang J
J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials.
Schmidt EV; Chisamore MJ; Chaney MF; Maradeo ME; Anderson J; Baltus GA; Pinheiro EM; Uebele VN
JAMA Netw Open; 2020 Feb; 3(2):e1920833. PubMed ID: 32049290
[TBL] [Abstract][Full Text] [Related]
16. Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536.
Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Rosas-Murrieta NH; Millán-Pérez Peña L
Expert Opin Ther Pat; 2020 Feb; 30(2):83-86. PubMed ID: 31874056
[No Abstract] [Full Text] [Related]
17. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
Pico de Coaña Y; Choudhury A; Kiessling R
Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
[TBL] [Abstract][Full Text] [Related]
18. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
19. New frontiers in oncology: Immune checkpoint inhibitors in combination therapy.
Romano G; Gawlinski A
Drugs Today (Barc); 2017 Feb; 53(2):103-115. PubMed ID: 28387388
[TBL] [Abstract][Full Text] [Related]
20. [Combinations of chemotherapy or radiotherapy with checkpoint inhibitors].
Ghiringhelli F
Biol Aujourdhui; 2018; 212(3-4):77-79. PubMed ID: 30973135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
